EUVIMEDEUVIMED entdecken
Crossref

Discovery and structure − activity relationships of 2,4,5-trimethoxyphenyl pyrimidine derivatives as selective D5 receptor partial agonists

Sakesh Kumar, Sumit K Rastogi, Subrata Roy, Kajal Sharma, Santosh Kumar, Debalina Maity, Diwan Chand, Sachin Vishwakarma, Jiaur R Gayen, Kinshuk R Srivastava, Ravindra Kumar, Prem N Yadav

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2024.107809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Sakesh Kumar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience and Ageing Biology Division, CSIR-Central Drug Research Institute, Lucknow, U.P., (226031), India; Academy of Scientific and Innovative …. Hauptthemen laut MEDLINE: Pyrimidines, Receptors, Dopamine D5. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Council of Scientific & Industrial Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dopamine receptors are therapeutic targets for the treatment of various neurological and psychiatric disorders, including Parkinson's and Alzheimer's. Previously, PF-06649751 (tavapadon), PF-2562 and PW0464 have been discovered as potent and selective G protein-biased D1/D5 receptor agonists with optimal pharmacokinetic properties. However, no selective D5R agonist has been reported yet. In this context, we designed and synthesized forty non-catecholamines-based pyrimidine derivatives and identified four pyrimidine derivatives as selective D5R partial agonists. Using cAMP-based GloSensor assay in transiently transfected HEK293T cells with human D1 or D5 receptors, we discovered that compound 5c (4-(4-bromophenyl)-6-(2,4,5-trimethoxyphenyl)pyrimidin-2-amine) exhibited modest D5R agonist activity. This leads us to explore various modifications of this scaffold to improve the D5 agonist potency and efficacy. Using molecular docking, and rational design followed by their evaluation at D1 and D5 receptors for agonist activity, we identified three new derivatives, 5j, 5h, and 5e. The most potent compound of this series 5j (4-(4-iodophenyl)-6-(2,4,5-trimethoxyphenyl)pyrimidin-2-amine), exhibited EC50 of 269.7 ± 6.6 nM. Mice microsomal stability studies revealed that 5j is quite stable (>70 % at 1 hr). Furthermore, pharmacokinetic analysis of 5j (20 mg/kg, p.o) in C57BL/6j mice showed that 5j is readily absorbed via oral route of dosing and also enters into the brain (plasma Tmax: 1 h, Cmax: 51.10 ± 13.51 ng/ml; Brain Tmax: 0.5 h, Cmax: 22.54 ± 4.08 ng/ml). We further determined the in-vivo effect of 5j on cognition in scopolamine-induced amnesia in C57BL/6j mice. We observed that 5j (10 mg/kg, p.o) alleviated scopolamine-induced impairment in short-term memory and social recognition, which were blocked by D1/D5 antagonist SCH23390 (0.1 mg/kg, i.p.). Furthermore, 5j did not exhibit any cytotoxicity (up to 10 µM) or in vivo acute toxicity up to 200 mg/kg (p.o). These results strongly suggest that 5j could be further developed for treating neurological disorders wherein the D5 receptors play pivotal roles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesReceptors, Dopamine D5HumansAnimalsStructure-Activity RelationshipMiceHEK293 CellsMolecular StructureDose-Response Relationship, DrugMaleDrug DiscoveryMolecular Docking SimulationDopamine AgonistsMice, Inbred C57BL

Stichwörter der Autor:innen

CognitionD5R agonistsGloSensorNon-catecholaminePyrimidine derivatives

Substanzen

PyrimidinesReceptors, Dopamine D5Dopamine Agonists

Autor:innen und Institutionen

  • Neuroscience and Ageing Biology Division, CSIR-Central Drug Research Institute, Lucknow, U.P., (226031), India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, U.P., (201002), India.
  • Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, U.P., (226031), India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, U.P., (201002), India.
  • Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, U.P., (226031), India.
  • Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow, U.P., (226031), India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, U.P., (201002), India; Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow, U.P., (226031), India.
  • Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, U.P., (226031), India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, U.P., (201002), India. Electronic addr…

Förderung

  • Council of Scientific & Industrial Research

Zitieren

APA

Kumar, S., Rastogi, S. K., Roy, S., Sharma, K., Kumar, S., Maity, D., Chand, D., Vishwakarma, S., Gayen, J. R., Srivastava, K. R., Kumar, R., & Yadav, P. N. (2024). Discovery and structure − activity relationships of 2,4,5-trimethoxyphenyl pyrimidine derivatives as selective D5 receptor partial agonists. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107809

Vancouver

Kumar S, Rastogi SK, Roy S, Sharma K, Kumar S, Maity D, et al. Discovery and structure − activity relationships of 2,4,5-trimethoxyphenyl pyrimidine derivatives as selective D5 receptor partial agonists. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107809

BibTeX
@article{Kumar2024,
  author = {Kumar, Sakesh and Rastogi, Sumit K and Roy, Subrata and Sharma, Kajal and Kumar, Santosh and Maity, Debalina and Chand, Diwan and Vishwakarma, Sachin and Gayen, Jiaur R and Srivastava, Kinshuk R and Kumar, Ravindra and Yadav, Prem N},
  title = {Discovery and structure − activity relationships of 2,4,5-trimethoxyphenyl pyrimidine derivatives as selective D5 receptor partial agonists},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2024.107809}
}
Kostenlos starten →